Search results for "CANCER STEM CELL"

showing 10 items of 220 documents

Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior

2019

Although generally benign, pituitary tumors frequently show local invasiveness and resistance to pharmacological therapy. After the demonstration of the existence of pituitary gland stem cells, over the past decade, the presence of a stem cell subpopulation in pituitary tumors has been investigated, analogous to the cancer stem cell model developed for malignant tumors. This review recapitulates the experimental evidence supporting the existence of a population of stem-like cells in pituitary tumors, focusing on their potential role in tumor initiation, progression, recurrence and resistance to pharmacological therapy.

0301 basic medicinePituitary glandrecurrencePharmacological therapyMini ReviewEndocrinology Diabetes and MetabolisminvasivenessPopulation030209 endocrinology & metabolismTumor initiationmedicine.disease_causelcsh:Diseases of the endocrine glands. Clinical endocrinologyresistance03 medical and health sciences0302 clinical medicineEndocrinologyCancer stem cellpituitary tumorsstem cellsmedicineeducationinvasiveness; pituitary tumors; recurrence; resistance; stem cells; tumourigenesiseducation.field_of_studylcsh:RC648-665business.industryPituitary tumorsmedicine.disease030104 developmental biologymedicine.anatomical_structuretumourigenesisCancer researchStem cellCarcinogenesisbusinessFrontiers in Endocrinology
researchProduct

3D polymeric supports promote the growth and progression of anaplastic thyroid carcinoma.

2020

Abstract Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy that accounts for the majority of deaths from all thyroid cancers. ATC exhibits invasiveness and highly resistance to conventional therapies which include cytotoxic chemotherapy, the combination of BRAF and MEK inhibition and, more recently, immunotherapies, that have shown promising but still limited results. A growing knowledge on ATC tumor biology is needed for developing more effective therapies with significant better survival. Researchers have begun to utilize 3D models to culture cancer cells for in vitro studies. In this work, C643 ATC cell line was cultured on polymeric scaffolds with high-interconnecte…

0301 basic medicinePolymersBiophysicsMalignancyStem cell markerThyroid Carcinoma AnaplasticBiochemistryMetastasis03 medical and health sciences0302 clinical medicineCancer stem cellCell Line TumormedicineBiomarkers TumorHumansDoxorubicin3D tumor model Anaplastic thyroid carcinoma Doxorubicin Polymeric scaffold Stem cell markersMolecular BiologyThyroid cancerCell ShapeCell ProliferationTissue Scaffoldsbusiness.industryThyroidCell Biologymedicine.disease030104 developmental biologymedicine.anatomical_structureDoxorubicin030220 oncology & carcinogenesisCancer cellCancer researchDisease ProgressionNeoplastic Stem Cellsbusinessmedicine.drugBiochemical and biophysical research communications
researchProduct

Betulinic Acid Kills Colon Cancer Stem Cells

2016

Cancer stem cells (CSCs) are considered to be the origin of cancer and it is suggested that they are resistant to chemotherapy. Current therapies fail to eradicate CSCs and therefore selecting a resistant cell subset that is able to facilitate tumor recurrences. Betulinic acid (BetA) is a broad acting natural compound, shown to induce cell death via the inhibition of the stearoyl-CoA- desaturase (SCD- 1). This enzyme converts saturated fatty acids into unsaturated fatty acids and is over-expressed in tumor cells. Here we show that BetA induces rapid cell death in all colon CSCs tested and is able to affect the CSCs directly as shown, via the loss of clonogenic capacity. Similar results were…

0301 basic medicineProgrammed cell deathColorectal cancerMedicine (miscellaneous)Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCancer stem cellBetulinic acidCell Line TumormedicineHumansEnzyme InhibitorsClonogenic assayCell DeathCancer stem cellStearoyl CoA-desaturaseCancerGeneral Medicinemedicine.diseaseBetulinic acidTriterpenesClone CellsColon cancerTumor resistance030104 developmental biologychemistryBiochemistryCell culture030220 oncology & carcinogenesisCancer treatmentColonic NeoplasmsMutationCancer researchNeoplastic Stem CellsStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioPentacyclic TriterpenesStearoyl-CoA DesaturaseCurrent stem cell research & therapy
researchProduct

Cancer stem cell-based models of colorectal cancer reveal molecular determinants of therapy resistance

2016

Abstract Colorectal cancer (CRC) therapy mainly relies on the use of conventional chemotherapeutic drugs combined, in a subset of patients, with epidermal growth factor receptor [EGFR]-targeting agents. Although CRC is considered a prototype of a cancer stem cell (CSC)-driven tumor, the effects of both conventional and targeted therapies on the CSC compartment are largely unknown. We have optimized a protocol for colorectal CSC isolation that allowed us to obtain CSC-enriched cultures from primary tumor specimens, with high efficiency. CSC isolation was followed by in vitro and in vivo validation, genetic characterization, and drug sensitivity analysis, thus generating panels of CSC lines w…

0301 basic medicineProteomicscancer stem cellsColorectal cancerDrug ResistanceMice SCIDAnti-EGFR therapy; Cancer stem cells; Cetuximab; Colorectal cancer; Proteomic arrays; Animals; Cells Cultured; Colorectal Neoplasms; Drug Resistance Neoplasm; Female; Gene Expression Profiling; Humans; Mice Inbred NOD; Mice SCID; Mice Transgenic; Microarray Analysis; Models Biological; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proteomics; Signal Transduction; Developmental Biology; Cell BiologyTransgenicMiceMice Inbred NODModelsproteomic arrayscetuximabcell biologyEpidermal growth factor receptorCells CulturedCulturedCetuximabbiologyGeneral MedicinePrimary tumorNeoplastic Stem CellsFemaleSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioStem cellColorectal Neoplasmsmedicine.drugSignal TransductionCellsMice Transgeniccolorectal cancerSCIDModels Biological03 medical and health sciencesdevelopmental biologyProteomic arrayCancer stem cellIn vivoSettore MED/04 - PATOLOGIA GENERALEmedicineAnimalsHumansProtein Kinase InhibitorsSettore MED/06 - ONCOLOGIA MEDICAMicroarray analysis techniquesbusiness.industryCancer stem cellGene Expression Profilingmedicine.diseaseMicroarray AnalysisBiological030104 developmental biologyanti-EGFR therapyDrug Resistance Neoplasmanti-EGFR therapy; cancer stem cells; cetuximab; colorectal cancer; proteomic arrays; cell biology; developmental biologyImmunologyCancer researchbiology.proteinNeoplasmInbred NODbusiness
researchProduct

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells

2020

ObjectiveCancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.DesignA collection of primary sphere cell cultures obtained from 60 CRC specimens was used to generate CR-CSC mouse avatars to preclinically validate therapeutic options. We also made use of the ChIP-seq analysis for transcriptional…

0301 basic medicineReceptor ErbB-2Colorectal cancerCetuximabcolorectal cancermedicine.disease_cause03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALECancer stem cellstem cellsTumor Cells CulturedmedicineAdjuvant therapyAnimalsHumansEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsMitogen-Activated Protein Kinase Kinasesdrug resistancebiologybusiness.industryGastroenterologyTrastuzumabmedicine.diseaseantibody targeted therapy030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinKRASPhosphatidylinositol 3-KinaseStem cellColorectal Neoplasmsbusiness
researchProduct

Molecular Insights Into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells

2020

Autophagy, a cellular self-digestion process that is activated in response to stress, has a functional role in tumor formation and progression. Cancer stem cells (CSCs) accounting for a minor proportion of total cancer cells-have distinct self-renewal and differentiation abilities and promote metastasis. Researchers have shown that a numeral number of natural products using traditional experimental methods have been revealed to target CSCs. However, the specific role of autophagy with respect to CSCs and tumorigenesis using natural products are still unknown. Currently, CSCs are considered to be one of the causative reasons underlying the failure of anticancer treatment as a result of tumor…

0301 basic medicineautophagycancer stem cellnatural productsReviewCell fate determinationBiologymedicine.disease_causeMetastasisCell and Developmental Biologystemness03 medical and health sciences0302 clinical medicineCancer stem cellmedicinelcsh:QH301-705.5Transcription factorAutophagychemoresistanceCancerCell Biologymedicine.diseaseTumor formation030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisCancer researchCarcinogenesisDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer

2018

The identification of oncogenic driver mutations in non-small-cell lung cancer (NSCLC) has led to the development of targeted drugs. Tyrosine kinase inhibitors (TKIs) directed against the epidermal growth factor receptor (EGFR) target lung tumours bearing EGFR-activating mutations. This new therapeutic strategy has greatly improved tumour response rates. However, drug resistance invariably occurs during TKI-based treatment. Epithelial-to-mesenchymal transition (EMT) is one of the resistance mechanisms identified in EGFR-mutated NSCLC treated with TKIs. In this review we gather together the most important findings on this phenomenon in relation to cancer stem cells and cancer epigenetics. We…

0301 basic medicinebiologybusiness.industrymedicine.drug_classmedicine.disease_causemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorrespiratory tract diseases03 medical and health sciences030104 developmental biology0302 clinical medicineCancer stem cell030220 oncology & carcinogenesisCancer researchmedicinebiology.proteinEpithelial–mesenchymal transitionEpidermal growth factor receptorCancer epigeneticsGeneral Agricultural and Biological SciencesCarcinogenesisbusinessLung cancerTyrosine kinaseBiological Reviews
researchProduct

Nobiletin and xanthohumol sensitize colorectal cancer stem cells to standard chemotherapy

2021

Simple Summary Colorectal cancer stem cells (CR-CSCs) play a pivotal role in the therapy resistance and relapse of CRC patients. Herein we demonstrate that new treatment approaches comprising polymethoxyflavones and prenylflavonoids extracted from Citrus sinensis and Humulus lupulus, respectively, hamper the viability of CR-CSCs as well as synergizing with 5-fluorouracil and oxaliplatin (FOX)-based chemotherapy. Extract fractions containing Nobiletin and Xanthohumol, in combination with chemotherapy, decreased stemness properties of CR-CSCs and restrained the outgrowth of chemoresistant metastatic CR-CSCs. These data pinpoint Nobiletin and Xanthohumol as efficacious anti-cancer compounds in…

0301 basic medicinecancer stem cellCancer ResearchAnti-cancer therapyColorectal cancermedicine.medical_treatmentArticleNobiletin03 medical and health sciences0302 clinical medicineCancer stem cellSettore MED/04 - PATOLOGIA GENERALEMedicineflavonoidClonogenic assayRC254-282FlavonoidsChemotherapybusiness.industryCancer stem cellsWnt signaling pathwayXanthohumolNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell cyclemedicine.diseaseColorectal cancerOxaliplatin030104 developmental biologyOncologyflavonoids; nobiletin; xanthohumol; anti-cancer therapy; cancer stem cells; colorectal cancer; natural biofunctional molecules030220 oncology & carcinogenesisCancer researchNatural biofunctional moleculesStem cellbusinessanti-cancer therapy; cancer stem cells; colorectal cancer; flavonoids; natural biofunctional molecules; nobiletin; xanthohumolmedicine.drug
researchProduct

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

2019

Abstract Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T-cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T-cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7+CD56bright NK cells as well as high serum concentrations of the CCR7 ligand CCL19. CCR7 expression and CCL19 secretion …

0301 basic medicinecancer stem cellCancer ResearchT cellImmunologyCellchemical and pharmacologic phenomenaBiologyMetastasis03 medical and health sciences0302 clinical medicineImmune systemCancer stem cellmedicineNK cellMelanomaneoplasmsimmune surveillanceMelanomaCCL19medicine.diseaseImmune checkpoint030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchmetastasi
researchProduct

Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.

2019

Triple-negative breast cancer (TNBC) is a form of BC characterized by high aggressiveness and therapy resistance probably determined by cancer stem cells. MCL1 is an antiapoptotic Bcl-2 family member that could limit the efficacy of anticancer agents as recombinant human tumor necrosis factor related apoptosis-inducing ligand (rh-TRAIL). Here, we investigated MCL1 expression in TNBC tissues and cells. We found MCL1 differentially expressed (upregulated or downregulated) in TNBC tissues. Furthermore, in comparison to the human mammary epithelial cells, we found that MDA-MB-231 cells show similar messenger RNA levels but higher MCL1 protein levels, whereas it resulted downregulated in MDA-MB-…

0301 basic medicinecancer stem cellIndolesPhysiologyCell SurvivalClinical BiochemistryCellPopulationApoptosisTNF-Related Apoptosis-Inducing Ligand03 medical and health sciences0302 clinical medicineCancer stem cellSettore BIO/10 - BiochimicaCell Line Tumormedicinerh-TRAILBiomarkers TumorGene silencingHumansViability assayGene SilencingeducationCell ShapeCell ProliferationMembrane Potential Mitochondrialeducation.field_of_studySulfonamidesChemistryCell growthCell CycleCell BiologyCell cycleRecombinant ProteinsGene Expression Regulation NeoplasticReceptors TNF-Related Apoptosis-Inducing Ligand030104 developmental biologymedicine.anatomical_structureMCL1ApoptosisDR4 receptor030220 oncology & carcinogenesisCancer researchtriple-negative breast cancerMyeloid Cell Leukemia Sequence 1 ProteinJournal of cellular physiology
researchProduct